Formula I Compounds Inhibiting eIF4A for Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a significant need for compounds that specifically inhibit eIF4A activity, particularly in the context of its role in cancer pathways, as existing technologies have limitations in effectively modulating eIF4A's regulation of cancer pathways.
Innovation Solution
Development of compounds according to Formula (I) and their stereoisomers, tautomers, or pharmaceutically acceptable salts, which are used as chemotherapeutic agents to inhibit eIF4A activity, thereby treating eIF4A-dependent conditions such as cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing technologies are used to modulate eIF4A regulation of cancer pathways, then general translation inhibition may occur, but specific inhibition of eIF4A activity in cancer pathways is insufficient
Solution Approach 1:
The patent applies local quality by designing compounds that specifically target eIF4A's role in cancer pathways rather than inhibiting all translation. The compounds are engineered to interact with specific structural features of eIF4A that are critical for its function in cancer cell translation, thereby achieving selective inhibition of cancer pathways while preserving normal physiological translation processes.
Solution Approach 2:
The patent employs parameter changes by modifying molecular parameters of the compounds to optimize their binding affinity and selectivity for eIF4A. By adjusting structural parameters such as molecular weight, hydrophobicity, and functional group composition, the compounds achieve enhanced specificity for eIF4A-mediated cancer pathways while maintaining appropriate pharmacokinetic properties.
2Object-affected harmful factors
If eIF4A activity is inhibited to treat cancer, then cancer pathway regulation is improved, but off-target effects on normal translation may occur
Solution Approach 1:
The patent applies partial action by designing compounds that achieve sufficient inhibition of eIF4A activity in cancer pathways without completely blocking all translation processes. The compounds are formulated to provide partial inhibition that is therapeutic for cancer while leaving enough translational capacity intact to maintain essential cellular functions and reduce off-target toxicity.
Solution Approach 2:
The patent uses eIF4A as an intermediary target that mediates between upstream cancer signaling pathways and downstream translation processes. By selectively inhibiting eIF4A, the compounds intercept cancer pathway signaling without directly affecting all translation machinery, thereby reducing off-target effects while maintaining therapeutic efficacy.
Data Source
AI summary
The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X, Y, R1, R2, R3a, R3b, R4a, R4b and R5 are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4A and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.